<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03830723</url>
  </required_header>
  <id_info>
    <org_study_id>ovord</org_study_id>
    <nct_id>NCT03830723</nct_id>
  </id_info>
  <brief_title>Personalized Insemination Treatment Study</brief_title>
  <acronym>PITS</acronym>
  <official_title>Effect of Personalized Dosages of Rekovelle on the Number of Mature Follicles Reached in Intra-uterine Insemination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OVO R &amp; D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OVO R &amp; D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended for women undergoing their first cycle of 3 intrauterine
      inseminations. All 3 inseminations will be personalized by using algorithms to determine the
      dose of study medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study medication dosage for the first insemination cycle will be based on the woman's age as
      well as her Anti-Mullerian Hormone (AMH) levels.

      Study medication dosage for the second and third insemination will depend on ovarian response
      (number of follicles) during previous insemination cycle and woman's age
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open-label, prospective, dose-finding, single centre pilot study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovarian response</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the dose-response Relationship of Rekovelle with respect to ovarian response in participants undergoing controlled ovarian stimulation for intrauterine insemination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate pregnancy rate 6-8 weeks after insemination by ultrasound</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility</condition>
  <condition>Intrauterine Insemination</condition>
  <condition>Reproduction</condition>
  <arm_group>
    <arm_group_label>Rekovelle (Follitropin delta)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will receive a prescription for study medication Rekovelle (follitropin delta)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin delta</intervention_name>
    <description>Study medication doses during all 3 insemination will be personalized using a suggested algorithm</description>
    <arm_group_label>Rekovelle (Follitropin delta)</arm_group_label>
    <other_name>Rekovelle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women having consented to the study

          -  Women followed at fertility center

          -  First IUI cycle

          -  Women between the ages of 18 to 42 inclusively at time of consent form signature

          -  AMH &lt; 35 pmol/L (4.9 ng/mL) in participants' file in the last 24 months

          -  At least one permeable Fallopian tube confirmed by laparoscopy, hysterosalpingography
             (HSG), hysterosalpingosonography (HSSG) or one pregnancy in the last 3 years

          -  Insemination with either partner or donor sperm

          -  Male partner semen analysis considered adequate for IUI in accordance to the centre's
             standard practice

          -  Menstrual cycles from 26 to 39 days

          -  Presence of both ovaries

        Exclusion Criteria:

          -  Unable to consent

          -  Body weight &gt;100 kg

          -  AMH ≥35 pmol/L (4.9 ng/mL) in participants' file in the last 24 months

          -  Severe malformation (unicornuate or bicornuate uterus) or uterine anomaly including
             fibroids ≥ 5 cm

          -  Uncontrolled thyroid or adrenal dysfunction

          -  Pituitary tumour

          -  Persistent ovarian cysts or enlargement not due to PCOS (Polycystic ovary syndrome) &gt;
             3 cm

          -  Anovulatory women

          -  Use of contraceptives in the last 3 months prior to start of stimulation

          -  Diagnosis of hydrosalpinx

          -  Malignancies

          -  Breast pathology incompatible with gonadotropin stimulation

          -  Hypersensitivity to follitropin delta or to any ingredient in the formulation

          -  Addition of other infertility medication that can influence follicle stimulation and
             maturation such as growth hormone (GH)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Fertile women undergoing intrauterine insemination</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Kadoch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>clinique ovo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nelly Delouya, RN</last_name>
    <phone>514.798.2000</phone>
    <phone_ext>759</phone_ext>
    <email>n.delouya@cliniqueovo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Ovo</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4P 2S4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Joseph, RN</last_name>
      <phone>514.798.2000</phone>
      <phone_ext>756</phone_ext>
      <email>l.joseph@cliniqueovo.com</email>
    </contact>
    <contact_backup>
      <last_name>Nelly Delouya, RN</last_name>
      <phone>514.798.2000</phone>
      <phone_ext>759</phone_ext>
      <email>n.delouya@cliniqueovo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

